CEM Store
Registered
For this article I would like to talk about Raloxifene (Ralox) and its many possible research applications. Ralox is a Selective Estrogen Receptor Modulator (SERM) and to fully understand what Ralox is and can do you need to first understand the basics of what a "SERM" is.
A SERM is a compound that selectively binds to estrogen receptors in various parts of the body. When this happens it alters the effects of estrogen in some tissues, like for example breast tissue. SERMs are known to have been first researched for its possible application in the treatment of some cancers but that is not Ralox's only function. Ralox has shown to have many other possible research areas from fertility to Gynecomastia (Gyno) prevention and many more; it truly is a multi-faceted compound worthy of research.
Ralox has been shown in research studies to positively affect male research subjects with fertility related issues. Ralox does this by affecting the hypothalamic-pituitary-testicular axis (HPTA) and causing an increase of gonadotropin levels in the body. This was found to be crucial for an enhanced rate of conception in test subjects with infertility issues.
Ralox has also been found to have a very positive effect in research subjects with hormone related osteoporosis. Ralox shows these positive effects by increasing bone mineral density. Ralox was also found not to blunt growth hormone (GH) in both male and female test subjects, this matters because it has been shown to be an issue with some other SERM compounds currently being researched.
Ralox has proven very efficient in the prevention of Gyno in hormonally dysfunctional test subjects, but does not fix the underlying issues of hormonal dysfunction. Ralox in my opinion is still a good option as part of research into the treatment and/or prevention of gyno, possibly along with other compounds that may positively affect the underlying hormonal issues like an aromatase inhibitor. Ralox does not "fix" gyno but rather blocks estrogen from binding to the receptors in the breast glands and limits estrogens affects there, even with active hormonal dysfunction.
Ralox has been found to be very safe and effective in many research studies and well tolerated by test subjects. Ralox is a very promising compound and I feel further research is warranted into its many positive effects and possible applications.
Check it out >> Raloxifene 120 - SERMs - Ancillaries
Ref:
1) Recommendations for raloxifene use in daily clinical practice in the Swiss setting.Lippuner K, Buchard PA, De Geyter C, Imthurn B, Lamy O, Litschgi M, Luzuy F, Schiessl K, Stute P, Birkh?user M. Recommendations for raloxifene use in daily clin... [Eur Spine J. 2012] - PubMed - NCBI
2) Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.Birzniece V, Sutanto S, Ho KK. Gender difference in the neuroendocr... [J Clin Endocrinol Metab. 2012] - PubMed - NCBI
3) The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D. The effect of selective estrogen receptor modu... [Fertil Steril. 2009] - PubMed - NCBI
4) Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in ... [J Pediatr. 2004] - PubMed - NCBI
Raloxifene 120 - SERMs - Ancillaries
A SERM is a compound that selectively binds to estrogen receptors in various parts of the body. When this happens it alters the effects of estrogen in some tissues, like for example breast tissue. SERMs are known to have been first researched for its possible application in the treatment of some cancers but that is not Ralox's only function. Ralox has shown to have many other possible research areas from fertility to Gynecomastia (Gyno) prevention and many more; it truly is a multi-faceted compound worthy of research.
Ralox has been shown in research studies to positively affect male research subjects with fertility related issues. Ralox does this by affecting the hypothalamic-pituitary-testicular axis (HPTA) and causing an increase of gonadotropin levels in the body. This was found to be crucial for an enhanced rate of conception in test subjects with infertility issues.
Ralox has also been found to have a very positive effect in research subjects with hormone related osteoporosis. Ralox shows these positive effects by increasing bone mineral density. Ralox was also found not to blunt growth hormone (GH) in both male and female test subjects, this matters because it has been shown to be an issue with some other SERM compounds currently being researched.
Ralox has proven very efficient in the prevention of Gyno in hormonally dysfunctional test subjects, but does not fix the underlying issues of hormonal dysfunction. Ralox in my opinion is still a good option as part of research into the treatment and/or prevention of gyno, possibly along with other compounds that may positively affect the underlying hormonal issues like an aromatase inhibitor. Ralox does not "fix" gyno but rather blocks estrogen from binding to the receptors in the breast glands and limits estrogens affects there, even with active hormonal dysfunction.
Ralox has been found to be very safe and effective in many research studies and well tolerated by test subjects. Ralox is a very promising compound and I feel further research is warranted into its many positive effects and possible applications.
Check it out >> Raloxifene 120 - SERMs - Ancillaries
Ref:
1) Recommendations for raloxifene use in daily clinical practice in the Swiss setting.Lippuner K, Buchard PA, De Geyter C, Imthurn B, Lamy O, Litschgi M, Luzuy F, Schiessl K, Stute P, Birkh?user M. Recommendations for raloxifene use in daily clin... [Eur Spine J. 2012] - PubMed - NCBI
2) Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.Birzniece V, Sutanto S, Ho KK. Gender difference in the neuroendocr... [J Clin Endocrinol Metab. 2012] - PubMed - NCBI
3) The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D. The effect of selective estrogen receptor modu... [Fertil Steril. 2009] - PubMed - NCBI
4) Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in ... [J Pediatr. 2004] - PubMed - NCBI
Raloxifene 120 - SERMs - Ancillaries
